Menu
Back to User profile » Dr Hiroyuki Kato
Papers published by Dr Hiroyuki Kato:
Associations of LRP5 and MTHFR Gene Variants with Osteoarthritis Prevalence in Elderly Women: A Japanese Cohort Survey Randomly Sampled from a Basic Resident Registry
Nakano M, Yui H, Kikugawa S, Tokida R, Sakai N, Kondo N, Endo N, Haro H, Shimodaira H, Suzuki T, Kato H, Takahashi J, Nakamura Y
Therapeutics and Clinical Risk Management 2021, 17:1065-1073
Published Date: 29 September 2021
Organ accumulation and carcinogenicity of highly dispersed multi-walled carbon nanotubes administered intravenously in transgenic rasH2 mice
Sobajima A, Haniu H, Nomura H, Tanaka M, Takizawa T, Kamanaka T, Aoki K, Okamoto M, Yoshida K, Sasaki J, Ajima K, Kuroda C, Ishida H, Okano S, Ueda K, Kato H, Saito N
International Journal of Nanomedicine 2019, 14:6465-6480
Published Date: 12 August 2019
Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers
Yoshida K, Okamoto M, Sasaki J, Kuroda C, Ishida H, Ueda K, Okano S, Ideta H, Kamanaka T, Sobajima A, Takizawa T, Kito M, Aoki K, Uemura T, Haniu H, Kato H, Saito N
OncoTargets and Therapy 2019, 12:2513-2518
Published Date: 3 April 2019
Efficacy of denosumab therapy for a 21-year-old woman with Prader-Willi syndrome, osteoporosis and history of fractures: a case report
Uehara M, Nakamura Y, Takahashi J, Suzuki T, Iijima M, Arakawa Y, Ida K, Kosho T, Kato H
Therapeutics and Clinical Risk Management 2019, 15:303-307
Published Date: 25 February 2019
Calcium and vitamin D supplementation with 3-year denosumab treatment is beneficial to enhance bone mineral density in postmenopausal patients with osteoporosis and rheumatoid arthritis
Suzuki T, Nakamura Y, Kato H
Therapeutics and Clinical Risk Management 2019, 15:15-22
Published Date: 18 December 2018
Different aggregation and shape characteristics of carbon materials affect biological responses in RAW264 cells
Kuroda C, Ueda K, Haniu H, Ishida H, Okano S, Takizawa T, Sobajima A, Kamanaka T, Yoshida K, Okamoto M, Tsukahara T, Matsuda Y, Aoki K, Kato H, Saito N
International Journal of Nanomedicine 2018, 13:6079-6088
Published Date: 5 October 2018
Efficacy of denosumab therapy for neurofibromatosis type I with osteoporosis and history of fractures: a case report
Uehara M, Nakamura Y, Takahashi J, Kamimura M, Isobe F, Yamaguchi T, Kosho T, Uchiyama S, Suzuki T, Kato H
Therapeutics and Clinical Risk Management 2018, 14:1243-1246
Published Date: 16 July 2018
Adequate nutrition status important for bone mineral density improvement in a patient with anorexia nervosa
Nakamura Y, Kamimura M, Koiwai H, Kato H
Therapeutics and Clinical Risk Management 2018, 14:945-948
Published Date: 18 May 2018
Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis
Uehara M, Nakamura Y, Takahashi J, Suzuki T, Kato H
Therapeutics and Clinical Risk Management 2018, 14:817-822
Published Date: 3 May 2018
Pre-treatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
Kamimura M, Taguchi A, Nakamura Y, Koiwai H, Ikegami S, Uchiyama S, Kato H
Therapeutics and Clinical Risk Management 2018, 14:637-642
Published Date: 3 April 2018
Significant improvement of bone mineral density by denosumab treatment in Japanese osteoporotic patients following breast cancer treatment
Nakamura Y, Kamimura M, Morikawa A, Taguchi A, Suzuki T, Kato H
Therapeutics and Clinical Risk Management 2018, 14:543-549
Published Date: 14 March 2018
Effects of denosumab on bone metabolism and bone mineral density with anti-TNF inhibitors, tocilizumab, or abatacept in osteoporosis with rheumatoid arthritis
Suzuki T, Nakamura Y, Kato H
Therapeutics and Clinical Risk Management 2018, 14:453-459
Published Date: 1 March 2018
Serum bone alkaline phosphatase is a useful marker to evaluate lumbar bone mineral density in Japanese postmenopausal osteoporotic women during denosumab treatment
Nakamura Y, Suzuki T, Kato H
Therapeutics and Clinical Risk Management 2017, 13:1343-1348
Published Date: 9 October 2017
Short-term bisphosphonate treatment reduces serum 25(OH) vitamin D3 and alters values of parathyroid hormone, pentosidine, and bone metabolic markers
Kamimura M, Uchiyama S, Nakamura Y, Ikegami S, Mukaiyama K, Kato H
Therapeutics and Clinical Risk Management 2017, 13:161-168
Published Date: 13 February 2017
A case series of pregnancy- and lactation-associated osteoporosis and a review of the literature
Nakamura Y, Kamimura M, Ikegami S, Mukaiyama K, Komatsu M, Uchiyama S, Kato H
Therapeutics and Clinical Risk Management 2015, 11:1361-1365
Published Date: 7 September 2015
Biological responses according to the shape and size of carbon nanotubes in BEAS-2B and MESO-1 cells
Haniu H, Saito N, Matsuda Y, Tsukahara T, Usui Y, Maruyama K, Takanashi S, Aoki K, Kobayashi S, Nomura H, Tanaka M, Okamoto M, Kato H
International Journal of Nanomedicine 2014, 9:1979-1990
Published Date: 17 April 2014
Elucidation mechanism of different biological responses to multi-walled carbon nanotubes using four cell lines
Haniu H, Saito N, Matsuda Y, Kim YA, Park KC, Tsukahara T, Usui Y, Aoki K, Shimizu M, Ogihara N, Hara K, Takanashi S, Okamoto M, Ishigaki N, Nakamura K, Kato H
International Journal of Nanomedicine 2011, 6:3487-3497
Published Date: 21 December 2011
Effect of dispersants of multi-walled carbon nanotubes on cellular uptake and biological responses
Haniu H, Saito N, Matsuda Y, Kim YA, Park KC, Tsukahara T, Usui Y, Aoki K, Shimizu M, Ogihara N, Hara K, Takanashi S, Okamoto M, Ishigaki N, Nakamura K, Kato H
International Journal of Nanomedicine 2011, 6:3295-3307
Published Date: 9 December 2011
DJ-1 as a potential biomarker for the development of biocompatible multiwalled carbon nanotubes
Haniu H, Tsukahara T, Matsuda Y, Usui Y, Aoki K, Shimizu M, Ogihara N, Hara K, Takanashi S, Okamoto M, Ishigaki N, Nakamura K, Kato H, Saito N
International Journal of Nanomedicine 2011, 6:2689-2695
Published Date: 4 November 2011